In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

A novel cardiac signal processing system for electrophysiology procedures: early insights from the pure ep 2.0 study

Session Invasive Electrophysiology from Electrophysiology System to Arrhythmia Mapping and Ablation

Speaker Carola Gianni

Event : ESC Congress 2020

  • Topic : arrhythmias and device therapy
  • Sub-topic : Arrhythmias, General: Invasive Diagnostic Methods
  • Session type : Best ePosters

Authors : C Gianni (Austin,US), A Al-Ahmad (Austin,US), B Knight (Chicago,US), W Tzou (Aurora,US), P Santangeli (Philadelphia,US), M Edzards (Westport,US), K Tarzia (Westport,US), J Lee (Westport,US), A Sharma (Westport,US), J Stephenson (Westport,US), S Bailey (Austin,US), R Horton (Austin,US), D Kessler (Austin,US), A Natale (Austin,US)

Authors:
C Gianni1 , A Al-Ahmad1 , B Knight2 , W Tzou3 , P Santangeli4 , M Edzards5 , K Tarzia5 , J Lee5 , A Sharma5 , J Stephenson5 , S Bailey1 , R Horton1 , D Kessler1 , A Natale1 , 1St. David's Medical Center, Texas Cardiac Arrhythmia Institute - Austin - United States of America , 2Northwestern University, Cardiac Electrophysiology - Chicago - United States of America , 3University of Colorado, Cardiac Electrophysiology - Aurora - United States of America , 4University of Pennsylvania, Cardiac Electrophysiology - Philadelphia - United States of America , 5BioSig Technologies - Westport - United States of America ,

Citation:

Background: Intracardiac electrogram data remain one of the primary diagnostic inputs guiding complex ablation procedures. However, the technology to collect, process, and display intracardiac signals has remained relatively unchanged for the past two decades.

Purpose: We test a new platform, the PURE EP™ 2.0 system (PEP; BioSig Technologies) for signal processing and display.

Methods:  Identical electrocardiographic and intracardiac signal data were recorded during 15 AF ablation procedures from the PEP system, the signal recording system, and the 3D mapping system (Figure). The collected signals underwent blinded, controlled evaluation by three independent electrophysiologist reviewers to determine whether the PEP signals are a viable alternative to conventional sources and if it provides additional or clearer diagnostic information.  Reviewers were asked to record the quality of each signal sample on a scale of 1-10 and select a rationale for their rating in a dropdown menu. Each paired signal rating was collected and unblinded for the analysis. If the reviewer rated the samples in the set within 1 point of each other, the PEP sample was deemed equivalent to the control.  Using a 2+1 statistical method, the ratings from the three reviewers were then compared looking for at least two positive reviews for each PEP sample.

Results: Based on the ratings for each pair of signals, a cumulative total of 29 PEP signals out of 34 (85.3%) were rated as statistically equivalent or better for this dataset. In 35.5% of samples, the reviewers selected PEP because "more signal components were visible." 

Conclusion: The PURE EP 2.0 system is able to produce reliable and high-quality signals when compared to available standard of care systems. Further studies with larger dataset across multiple sites are needed to validate these results.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are